ClariVest Asset Management LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 14.3% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 386,472 shares of the medical research company’s stock after buying an additional 48,271 shares during the period. Amgen comprises about 1.8% of ClariVest Asset Management LLC’s portfolio, making the stock its 8th largest position. ClariVest Asset Management LLC owned about 0.05% of Amgen worth $58,802,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Community Bank & Trust Waco Texas boosted its position in shares of Amgen by 131.9% in the first quarter. Community Bank & Trust Waco Texas now owns 3,399 shares of the medical research company’s stock worth $510,000 after buying an additional 1,933 shares during the last quarter. Virginia Retirement System bought a new position in shares of Amgen during the first quarter worth about $25,392,000. Outfitter Advisors LTD. boosted its position in shares of Amgen by 2.6% in the first quarter. Outfitter Advisors LTD. now owns 3,992 shares of the medical research company’s stock worth $599,000 after buying an additional 100 shares during the last quarter. Tiemann Investment Advisors LLC bought a new position in shares of Amgen during the first quarter worth about $226,000. Finally, Badgley Phelps & Bell Inc. boosted its position in shares of Amgen by 12.1% in the first quarter. Badgley Phelps & Bell Inc. now owns 28,150 shares of the medical research company’s stock worth $4,221,000 after buying an additional 3,048 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) traded down 1.45% during midday trading on Friday, hitting $161.90. The stock had a trading volume of 2,817,469 shares. The company’s 50 day moving average is $169.59 and its 200 day moving average is $162.28. The company has a market cap of $121.16 billion, a price-to-earnings ratio of 16.57 and a beta of 0.94. Amgen Inc. has a 1-year low of $139.02 and a 1-year high of $176.85.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. During the same period last year, the business posted $2.57 EPS. Amgen’s revenue was up 5.9% on a year-over-year basis. On average, equities analysts anticipate that Amgen Inc. will post $11.35 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Investors of record on Wednesday, November 16th will be paid a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.47%. Amgen’s dividend payout ratio (DPR) is currently 40.90%.

A number of research analysts have recently weighed in on the company. BMO Capital Markets reiterated an “outperform” rating and set a $190.00 price target on shares of Amgen in a report on Thursday, September 22nd. Jefferies Group reiterated a “buy” rating and set a $198.00 price target on shares of Amgen in a report on Tuesday, August 23rd. Vetr upgraded Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target on the stock in a report on Wednesday, August 3rd. Leerink Swann reiterated a “hold” rating on shares of Amgen in a report on Saturday, September 17th. Finally, Credit Suisse Group AG set a $206.00 price target on Amgen and gave the company a “buy” rating in a report on Saturday, September 17th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. Amgen has a consensus rating of “Buy” and an average price target of $184.94.

In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

5 Day Chart for NASDAQ:AMGN

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.